New injection could train your body to fight cancer from within
NCT ID NCT07240974
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called ZZSW-01 in 6 people with B-cell blood cancers that have come back or not responded to other treatments. The drug is a special particle that carries instructions for the body to make its own cancer-fighting cells. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZZSW-01 injection (a type of CAR mRNA therapy delivered via extracellular vesicles to create CAR-T cells inside the body)
What this could lead to
If successful, this could lead to a new, simpler way to treat certain blood cancers without needing to extract and modify a patient's own cells.
What could go wrong
This is a very early, tiny study with only 6 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome and nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, 430022, China